Attached files
| file | filename |
|---|---|
| EX-31.2 - EX-31.2 - Spero Therapeutics, Inc. | spro-20210630ex31_2.htm |
| EX-31.1 - EX-31.1 - Spero Therapeutics, Inc. | spro-20210630ex31_1.htm |
| EX-10.2 - EX-10.2 - Spero Therapeutics, Inc. | spro-20210630ex10_2.htm |
| EX-10.1 - EX-10.1 - Spero Therapeutics, Inc. | spro-20210630ex10_1.htm |
| 10-Q - 10-Q - Spero Therapeutics, Inc. | spro-20210630.htm |
Exhibit 32
CERTIFICATIONS UNDER SECTION 906
Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Spero Therapeutics, Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:
The Quarterly Report for the quarter ended June 30, 2021 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: August 5, 2021 |
/s/ Ankit Mahadevia, M.D. |
|
Ankit Mahadevia, M.D. |
|
President and Chief Executive Officer |
|
(Principal Executive Officer) |
Dated: August 5, 2021 |
/s/ Satyavrat Shukla |
|
Satyavrat Shukla |
|
Chief Financial Officer and Treasurer |
|
(Principal Financial Officer) |